CAR-T Therapy Shows Over 10-Year Remissions in B-Cell Lymphoma Patients
CAR-T cell therapy has achieved unprecedented 10-year remission rates in patients with relapsed/refractory B-cell lymphoma, according to data published this week in Gènéthique, marking a potential paradigm shift in hematologic ... Read More